BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34898148)

  • 21. Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage.
    Prescrire Int; 2016 Dec; 25(177):289-292. PubMed ID: 30758924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of COVID-19 Pandemic on the Diagnosis of Melanoma and Keratinocyte Carcinomas: a Systematic Review and Meta-analysis.
    Díaz-Calvillo P; Muñoz-Barba D; Ureña-Paniego C; Maul LV; Cerminara S; Kostner L; Martínez López A; Arias-Santiago S
    Acta Derm Venereol; 2024 Mar; 104():adv19460. PubMed ID: 38483083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID infection and sentinel lymph node procedure for melanoma: Management in a dermato-oncology center in a high-risk pandemic area.
    Caliendo V; Picciotto F; Quaglino P; Ribero S
    Dermatol Ther; 2020 Jul; 33(4):e13536. PubMed ID: 32385893
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent Advances in Melanoma Tumorigenesis.
    Bernhardt M; Bernhardt A
    J Drugs Dermatol; 2022 Dec; 21(12):1289-1293. PubMed ID: 36468958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of COVID-19 pandemic on health equality in malignant melanoma diagnosis.
    Lun LK; Cheng H; Hussain R
    Clin Med (Lond); 2023 Nov; 23(Suppl 6):62. PubMed ID: 38182253
    [No Abstract]   [Full Text] [Related]  

  • 26. The Epidemiology of Malignant Melanoma during the First Two Years of the COVID-19 Pandemic: A Systematic Review.
    Toma AO; Prodan M; Reddyreddy AR; Seclaman E; Crainiceanu Z; Bloanca V; Bratosin F; Dumitru C; Pilut CN; Alambaram S; Vasamsetti NG; Decean L; Pricop M
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Impact of COVID pandemic on the detection of skin cancer].
    Triboulet C; Amblas A; Vernez M; Michielin O; Gaide O
    Rev Med Suisse; 2021 Mar; 17(732):635-639. PubMed ID: 33793101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Three independent melanomas over a span of 2 years in a 31-year-old man-a case report].
    Hübner M; Vandersee S
    Hautarzt; 2020 Jun; 71(6):435-436. PubMed ID: 32333040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histological types of polypoid cutaneous melanoma II.
    Knezević F; Duancić V; Sitić S; Horvat-Knezević A; Benković V; Ramić S; Kostović K; Ramljak V; Vrdoljak DV; Stanec M; Bozović A
    Coll Antropol; 2007 Dec; 31(4):1049-53. PubMed ID: 18217457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Did COVID-19 lockdown delay actually worsen melanoma prognosis?
    Gil-Pallares P; Figueroa-Silva O; Gil-Pallares ME; Vázquez-Bueno JÁ; Piñeyro-Molina F; Monteagudo B; Heras-Sotos CL
    An Bras Dermatol; 2023; 98(2):176-180. PubMed ID: 36567164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of reports about the impact of the COVID-19 pandemic on melanoma diagnosis.
    Ricci F; Abeni D
    Br J Dermatol; 2022 Aug; 187(2):135-136. PubMed ID: 35610054
    [No Abstract]   [Full Text] [Related]  

  • 32. Virtual melanoma checks during a pandemic.
    Janda M; Swetter SM; Horsham C; Soyer HP
    Br J Dermatol; 2020 Oct; 183(4):752-753. PubMed ID: 32471016
    [No Abstract]   [Full Text] [Related]  

  • 33. Reduced melanoma referrals during COVID-19 lockdown.
    Berry W; Tan K; Haydon A; Shackleton M; Mar VJ
    Aust J Gen Pract; 2021 Jan; 50():. PubMed ID: 33543153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A significant reduction in the diagnosis of melanoma during the COVID-19 lockdown in a third-level center in the Northern Italy.
    Barruscotti S; Giorgini C; Brazzelli V; Vassallo C; Michelerio A; Klersy C; Chiellino S; Tomasini CF
    Dermatol Ther; 2020 Nov; 33(6):e14074. PubMed ID: 32713046
    [No Abstract]   [Full Text] [Related]  

  • 35. Polypoid melanoma, a virulent variant of the nodular growth pattern.
    Manci EA; Balch CM; Murad TM; Soong SJ
    Am J Clin Pathol; 1981 Jun; 75(6):810-5. PubMed ID: 7258141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
    Kilickap S; Guven DC; Aktepe OH; Aktas BY; Dizdar O
    J Oncol Pharm Pract; 2020 Mar; 26(2):496-499. PubMed ID: 31256744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attitudes of Patients With Skin Tumors During the COVID-19 Pandemic.
    Porcar Saura S; Pons Benavent M; Guillén Climent S; García Vázquez A
    Actas Dermosifiliogr (Engl Ed); 2021 Feb; 112(2):195-198. PubMed ID: 32905789
    [No Abstract]   [Full Text] [Related]  

  • 38. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
    Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
    J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    McDonald MA; Sanghvi P; Bykowski J; Daniels GA
    BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of COVID-19 on melanoma diagnosis.
    Weston GK; Jeong HS; Mu EW; Polsky D; Meehan SA
    Melanoma Res; 2021 Jun; 31(3):280-281. PubMed ID: 33625106
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.